Toxicity and Antiinflammatory Effect of 1,5-Bis(3’-Ethoxy-4’-Hydroxyphenyl)-1,4- Pentadiene-3-One (EHP)
Abstract
The 1,5-bis(3’-ethoxy-4’-hydroxyphenyl)-1,4-pentadiene -3-one (EHP) is a curcumin analogue. The structure has also been identified before. EHP is obtained, which has been pharmacologically proven to have higher antioxidant activity than curcumin. The objectives of this research were to determine the acute toxicity (LD50) of EHP compound by Weil C.S. method using male mice as experimental animals and to determine its antiinflammatory activity. The LD50 value of the synthesized EHP compound is 6,8675 g/kg body weight (bw) with the criteria of mild toxic, so it is assumed to be safe as drug substance candidate. The anti-inflammatory activity of the compound was determined by obeserved legs swelling index of the mouse. Anti-inflammatory activity of EHP with doses of 137.35 mg, 274.70 mg and 549.40 mg were equal to aspirin with the dose of 90 mg/200 g bw
References
2. Sardjiman SS, Samhoedi M, Hakim L, Vandergoot H, Timmerman H. Synthesis and structure activity relationship 1,5-diphenyl-1,4-pentadien-3-ones-and cycly analogues an antioxidative agent. Yogyakarta: Faculty of Pharmacy, Gadjah Mada University; 2003. 175-84.
3. Esti M, Indriana P, Evi L, Enjang R. Sintesis dan uji antioksidan senyawa 1,5-bis(3’-etoksi- 4’-hidroksifenil)-1,4-pentadien-3-on. Jurnal Ilmu Kefarmasian Indonesia. 2010. 8(2): 93-102. 4. Esti M, Agus N, Mayagustina A, Bambang SAS. The molecular docking of 1,5-diphenil-1,4-pentadien-3- on derivates as the inhibitor of COX-2 enzyme. Henk
Timmerman International Seminar& Awards (HTSIA) on Structure Based Drug Design, Yogyakarta, 2009.
5. Esti M, Budi I, Mayagustina A, Bambang SAS. Docking molekul derivat 1,5-difenil-1,4-pentadien- 3-on sebagai inhibitor enzim LOX-5. Seminar dan Kongres Nasional ISFI, Jakarta, 2009.
6. Lu FC. Toksikologi, dasar asas, organ sasaran, dan penelitian resiko. Edisi 2. Diterjemahkan oleh Edi Nugroho. Jakarta: UI Press; 1995.
7. Weil CS. Table for convinent calculation of median effective dose (LD50) and instruction in their use biometrics. 1952.
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Tools
